查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1731669

高尿酸血症藥物市場：未來預測（2025-2030）

Hyperuricemia Treatment Market - Forecasts from 2025 to 2030
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 149 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

高尿酸血症治療市場預計將以 6.31% 的複合年成長率成長，從 2025 年的 31.88 億美元成長到 2030 年的 43.29 億美元。

高尿酸血症是一種以體內血清尿酸濃度升高為特徵的疾病，一般女性為 6 mg/dL 或更高，男性為 7 mg/dL 或更高。高尿酸血症是由於尿酸生成增加、排泄減少或兩者兼而有之所致。血尿酸水平升高會導致痛風、腎結石、腎臟損傷、慢性腎臟病等疾病，並與一系列相關疾病有關，包括心血管疾病、糖尿病、高血壓、脂肪肝和乾癬。根據美國國家生物技術資訊中心的數據，估計21%的一般人群和25%的住院患者患有無症狀性高尿酸血症。

市場趨勢：

  • 科技進步促進診斷和治療

高尿酸血症管理的技術創新透過增強診斷和治療推動了市場成長。發展包括先進的生物標記識別、基因檢測和減少尿酸產生的促尿酸排泄藥物。基於奈米粒子的標靶治療等新型藥物傳輸系統也越來越受歡迎。聚乙二醇重組尿酸酶（pegadricase）與mTOR抑制劑免疫耐受技術（ImmTOR™）的組合等精準醫療研究正在重新定義痛風治療。研究機構和大學的持續研發努力透過為高尿酸血症及其相關疾病提供創新解決方案繼續推動市場擴張。

  • 亞太地區是一個快速成長的市場

預計在預測期內，亞太地區高尿酸血症市場將出現最快的成長，這主要是由於久坐不動的生活方式、肥胖、糖尿病和高血壓導致的高尿酸血症盛行率不斷上升。印度（盛行率為 44.6%）和中國（根據 2017 年 NHANES 的數據，盛行率為 17.7%）等國家的病例數正在增加。醫療保健服務的改善和意識的提高進一步促進了市場的成長。

  • 北美保持較大的市場佔有率

受先進的醫療基礎設施、人口老化和久坐不動的生活方式的推動，北美佔據高尿酸血症市場的很大佔有率。美國健康與營養檢查調查估計，21%（4,300萬）的美國成年人和20.6%的墨西哥人患有高尿酸血症。根據美國國家糖尿病、消化和腎臟疾病研究所的報告，11%的男性和6%的女性曾經患有腎結石，慢性腎臟病在65歲以上的人群中最為常見（34%）。這些因素加上人口老化正在推動該地區的市場成長。

本報告介紹的主要企業包括日本化學製藥公司、Astellas製藥公司、Astra Zeneca、梯瓦製藥工業有限公司、默克公司、賽諾菲公司和輝瑞公司。

本報告的主要優點

  • 深刻分析：獲得涵蓋主要地區和新興地區的深入市場洞察，重點關注客戶群、政府政策和社會經濟因素、消費者偏好、垂直行業和其他子區隔。
  • 競爭格局：了解全球主要企業所採用的策略策略，並了解正確策略帶來的潛在市場滲透。
  • 市場促進因素和未來趨勢：探索動態因素和關鍵市場趨勢以及它們將如何影響市場的未來發展。
  • 可行的建議：利用洞察力進行策略決策，在動態環境中開闢新的業務流和收益。
  • 適用範圍廣：對於新興企業、研究機構、顧問公司、中小企業和大型企業來說，它都是實用且具有成本效益的。

它有什麼用途？

產業與市場洞察、商業機會評估、產品需求預測、打入市場策略、地理擴張、資本支出決策、法律規範與影響、新產品開發、競爭影響

分析範圍

  • 歷史資料（2022-2024）和預測資料（2025-2030）
  • 成長機會、挑戰、供應鏈前景、法規結構、顧客行為、趨勢分析
  • 競爭對手定位、策略和市場佔有率分析
  • 按部門和地區（國家）分類的收益成長和預測分析
  • 公司概況（策略、產品、財務資訊、主要趨勢等）

目錄

第1章 引言

  • 市場概覽
  • 市場定義
  • 分析範圍
  • 市場區隔
  • 貨幣
  • 先決條件
  • 基準年和預測年時間表
  • 相關利益者的主要利益

第2章 分析方法

  • 分析設計
  • 分析過程

第3章執行摘要

  • 主要發現
  • CXO觀點

第4章 市場動態

  • 市場促進因素
  • 市場限制
  • 波特五力分析
  • 產業價值鏈分析
  • 分析師觀點

第5章 高尿酸血症藥物市場（依疾病類型）

  • 介紹
  • 痛風
  • 慢性腎臟病
  • 其他

第6章 高尿酸血症藥物市場（依治療方法）

  • 介紹
  • 尿酸排泄促進劑
  • 黃嘌呤氧化酶抑制劑
  • 重組尿酸酶
  • 非藥物干預
  • 其他

第7章 高尿酸血症藥物市場（依最終使用者）

  • 介紹
  • 醫院
  • 診所
  • 其他

第8章 高尿酸血症藥物市場（按地區）

  • 介紹
  • 北美洲
    • 依疾病類型
    • 治療方法
    • 按最終用戶
    • 按國家
      • 美國
      • 加拿大
      • 墨西哥
  • 南美洲
    • 依疾病類型
    • 治療方法
    • 按最終用戶
    • 按國家
      • 巴西
      • 阿根廷
      • 其他
  • 歐洲
    • 依疾病類型
    • 治療方法
    • 按最終用戶
    • 按國家
      • 英國
      • 德國
      • 法國
      • 西班牙
      • 其他
  • 中東和非洲
    • 依疾病類型
    • 治療方法
    • 按最終用戶
    • 按國家
      • 沙烏地阿拉伯
      • 阿拉伯聯合大公國
      • 其他
  • 亞太地區
    • 依疾病類型
    • 治療方法
    • 按最終用戶
    • 按國家
      • 中國
      • 日本
      • 韓國
      • 澳洲
      • 印度
      • 印尼
      • 泰國
      • 其他

第9章競爭格局及分析

  • 主要企業和策略分析
  • 市場佔有率分析
  • 企業合併、協議、商業合作
  • 競爭儀錶板

第10章 公司簡介

  • Nippon Chemiphar
  • Astellas Pharma
  • AstraZeneca
  • Tonghua Dongbao Pharmaceutical
  • Teva Pharmaceutical Industries Ltd.
  • Merck & Co.
  • Sanofi SA
  • Pfizer Inc.
  • Amgen Inc.
  • Takeda Pharmaceutical Company Limited
  • Novartis AG
  • GlaxoSmithKline plc
  • Kissei Pharmaceutical Co., Ltd.
簡介目錄
Product Code: KSI061617342

The Hyperuricemia Treatment Market is expected to grow at a CAGR of 6.31%, reaching a market size of US$4.329 billion in 2030 from US$3.188 billion in 2025

Hyperuricemia is a condition characterised by elevated levels of serum uric acid in the body, generally greater than 6 mg/dL in women and 7 mg/dL in men. It results from increased uric acid production, decreased excretion or a combination of both factors. This increase in the level of uric acid in the blood leads to disorders like gout, kidney stones, renal disorders, and chronic kidney diseases and is linked to many other related diseases like cardiovascular diseases, diabetes, hypertension, fatty liver disease, Psoriasis and some others. As per the data from the National Center for Biotechnology Information, up to 21% of the general population and 25% of hospitalized patients are estimated to have asymptomatic hyperuricemia.

Market Trends:

  • Technological Advancements Propel Diagnosis and Treatment

Innovations in hyperuricemia management are accelerating market growth through enhanced diagnostics and therapies. Developments include advanced biomarker identification, genetic testing, and uricosuric drugs that reduce uric acid production. Novel drug delivery systems, such as nanoparticle-based targeted therapies, are also gaining traction. Research into precision treatments, like the combination of pegylated recombinant uricase (pegadricase) and immune tolerance technology for mTOR inhibitors (ImmTOR(TM)), is redefining gout therapy. Ongoing R&D efforts by institutions and universities continue to drive market expansion by offering innovative solutions for hyperuricemia and associated conditions.

  • Asia Pacific to Experience Rapid Market Growth

The Asia Pacific region is projected to be the fastest-growing hyperuricemia market during the forecast period, driven by increasing prevalence due to sedentary lifestyles, obesity, diabetes, and hypertension. Countries like India (44.6% prevalence) and China (17.7% in 2017, per NHANES) are seeing rising cases. Improved healthcare access and growing awareness further contribute to market growth.

  • North America Maintains Significant Market Share

North America holds a substantial share of the hyperuricemia market, supported by advanced healthcare infrastructure, an aging population, and sedentary lifestyles. The U.S. National Health and Nutrition Examination Survey estimates 21% of U.S. adults (43 million) and 20.6% of Mexicans have hyperuricemia. The National Institute of Diabetes and Digestive and Kidney Diseases reports that 11% of men and 6% of women experience kidney stones, with chronic kidney disease most prevalent among those aged 65+ (34%). These factors, combined with the aging demographic, drive market growth in the region.

Some of the major players covered in this report include Nippon Chemiphar, Astellas Pharma, AstraZeneca, Tonghua Dongbao Pharmaceutical, Teva Pharmaceutical Industries Ltd., Merck & Co., Sanofi SA, Pfizer Inc., among others.

Key Benefits of this Report:

  • Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
  • Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
  • Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
  • Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
  • Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

  • Historical data from 2022 to 2024 & forecast data from 2025 to 2030
  • Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
  • Competitive Positioning, Strategies, and Market Share Analysis
  • Revenue Growth and Forecast Assessment of segments and regions including countries
  • Company Profiling (Strategies, Products, Financial Information, and Key Developments among others)

The Hyperuricemia Treatment Market is analysed into the following segments:

By Type of Disease

  • Gout
  • Chronic Kidney Diseases
  • Others

By Treatment Method

  • Uricosuric agents
  • Xanthine Oxidase Inhibitors
  • Recombinant Uricases
  • Non-Pharmacological Interventions
  • Others

By End-User

  • Hospitals
  • Clinics
  • Others

By Geography

  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • United Kingdom
  • Germany
  • France
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Others
  • Asia Pacific
  • China
  • Japan
  • South Korea
  • Australia
  • India
  • Indonesia
  • Thailand
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base and Forecast Years Timeline
  • 1.8. Key Benefits to the Stakeholder

2. RESEARCH METHODOLOGY

  • 2.1. Research Design
  • 2.2. Research Processes

3. EXECUTIVE SUMMARY

  • 3.1. Key Findings
  • 3.2. CXO Perspective

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis
  • 4.5. Analyst View

5. HYPERURICEMIA TREATMENT MARKET BY TYPE OF DISEASE

  • 5.1. Introduction
  • 5.2. Gout
  • 5.3. Chronic Kidney Diseases
  • 5.4. Others

6. HYPERURICEMIA TREATMENT MARKET BY TREATMENT METHOD

  • 6.1. Introduction
  • 6.2. Uricosuric agents
  • 6.3. Xanthine Oxidase Inhibitors
  • 6.4. Recombinant Uricases
  • 6.5. Non-Pharmacological Interventions
  • 6.6. Others

7. HYPERURICEMIA TREATMENT MARKET BY END-USER

  • 7.1. Introduction
  • 7.2. Hospitals
  • 7.3. Clinics
  • 7.4. Others

8. HYPERURICEMIA TREATMENT MARKET BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. By Type of Disease
    • 8.2.2. By Treatment Method
    • 8.2.3. By End-User
    • 8.2.4. By Country
      • 8.2.4.1. USA
      • 8.2.4.2. Canada
      • 8.2.4.3. Mexico
  • 8.3. South America
    • 8.3.1. By Type of Disease
    • 8.3.2. By Treatment Method
    • 8.3.3. By End-User
    • 8.3.4. By Country
      • 8.3.4.1. Brazil
      • 8.3.4.2. Argentina
      • 8.3.4.3. Others
  • 8.4. Europe
    • 8.4.1. By Type of Disease
    • 8.4.2. By Treatment Method
    • 8.4.3. By End-User
    • 8.4.4. By Country
      • 8.4.4.1. United Kingdom
      • 8.4.4.2. Germany
      • 8.4.4.3. France
      • 8.4.4.4. Spain
      • 8.4.4.5. Others
  • 8.5. Middle East and Africa
    • 8.5.1. By Type of Disease
    • 8.5.2. By Treatment Method
    • 8.5.3. By End-User
    • 8.5.4. By Country
      • 8.5.4.1. Saudi Arabia
      • 8.5.4.2. UAE
      • 8.5.4.3. Others
  • 8.6. Asia Pacific
    • 8.6.1. By Type of Disease
    • 8.6.2. By Treatment Method
    • 8.6.3. By End-User
    • 8.6.4. By Country
      • 8.6.4.1. China
      • 8.6.4.2. Japan
      • 8.6.4.3. South Korea
      • 8.6.4.4. Australia
      • 8.6.4.5. India
      • 8.6.4.6. Indonesia
      • 8.6.4.7. Thailand
      • 8.6.4.8. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Market Share Analysis
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 9.4. Competitive Dashboard

10. COMPANY PROFILES

  • 10.1. Nippon Chemiphar
  • 10.2. Astellas Pharma
  • 10.3. AstraZeneca
  • 10.4. Tonghua Dongbao Pharmaceutical
  • 10.5. Teva Pharmaceutical Industries Ltd.
  • 10.6. Merck & Co.
  • 10.7. Sanofi SA
  • 10.8. Pfizer Inc.
  • 10.9. Amgen Inc.
  • 10.10. Takeda Pharmaceutical Company Limited
  • 10.11. Novartis AG
  • 10.12. GlaxoSmithKline plc
  • 10.13. Kissei Pharmaceutical Co., Ltd.